A Phase 2/3 interventional study of tamsulosin hydrochloride and Placebo in Bladder, Neurogenic, sponsored by Boehringer Ingelheim. Completed at 52 sites in 13 countries. Open to participants aged 2 Years to 16 Years. Per ClinicalTrials.gov, last updated 2015-10-29.
Sponsored by Boehringer Ingelheim · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Aim of this study is to evaluate the efficacy and safety of a range of doses of tamsulosin hydrochloride as treatment in children with an elevated detrusor leak point pressure associated with a known neurological deficit
191 studies on the registry are indexed under Urinary Bladder, Neurogenic; 40 are open to participants now.
This study's enrollment of 231 is above the median of 40 across 126 interventional studies indexed under Urinary Bladder, Neurogenic.
Browse Urinary Bladder, Neurogenic studies →Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received matching placebo to tamsulosin hydrochloride via opened capsules every day for 14 weeks
Drug: Placebo
Participants received 0.001 - 0.002 mg/kg tamsulosin hydrochloride via opened capsules every day for 14 weeks
Drug: tamsulosin hydrochloride
Participants received 0.002 - 0.004 mg/kg tamsulosin hydrochloride via opened capsules every day for 14 weeks
Drug: tamsulosin hydrochloride
Participants received 0.004 - 0.008 mg/kg tamsulosin hydrochloride via opened capsules every day for 14 weeks
Drug: tamsulosin hydrochloride
Oral
Also known as: Flomax, Omnic
Oral
Response to Treatment Defined as Patients Who Decrease Their Detrusor Leak Point Pressure (LPP) to <40 cm H2O Based Upon Two Evaluations on the Same Day.
The primary endpoint was response to treatment defined as patients who decreased their detrusor leak point pressure (LPP) based upon two evaluations on the same day to less than 40 cm H2O at Week 14 (end of treatment). Detrusor leak point pressure (LPP) recorded in cm H2O was obtained using a standard urodynamic technique, a cystometrogram. On treatment (OT): Consist of all on treatment data. Observations measured ≤3 days of stopping treatment was considered as on treatment. Missing data in these analyses was not replaced or imputed.
Time frame: Week 14
Change From Baseline in LPP at Week 14 (End of Treatment)
Change from baseline in detrusor leak point pressure (LPP) at Week 14 (end of treatment) between each dose group and the placebo group was compared for the FAS-LPP.
Time frame: Baseline and Week 14
Percentage Change From Baseline in LPP at Week 14 (End of Treatment)
Percent changes in detrusor leak point pressure (LPP) from baseline to the end of treatment at Week 14 between each dose group and the placebo group were compared for the FAS-LPP.
Time frame: Baseline and Week 14.
Response With Regard to Hydronephrosis Was Defined as Improvement or Stabilisation Based Upon the Renal Ultrasound Grading at Week 14 (End of Treatment) Compared to Baseline
Hydronephrosis response was defined as stabilisation or improvement of hydronephrosis measured by renal ultrasound at the end of treatment when compared to baseline, based on ultrasound grading. The lower or same grade at end of treatment compared to baseline is considered an improvement or stabilization
Time frame: Baseline and Week 14
Response With Regard to Hydroureter Was Defined as Improvement or Stabilisation Based Upon the Renal Ultrasound at Week 14 (End of Treatment) Compared to Baseline
Hydroureter response was defined as stabilisation or improvement based on change from baseline in the presence or absence of hydroureter at the end of treatment (Week 14). Response defined as stabilization or improvement of hydroureter measured by renal ultrasound compared to baseline by treatment group (Patients are classified according to the treatment they were taking at Week 14 or end of treatment) at Week 14.
Time frame: Baseline and Week 14
Change From Baseline in Urine Volume at Week 14
Change in baseline urine volumes obtained by catheterisation as recorded in catheterisation diary at Week 14.
Time frame: Baseline and Week 14
Change From Baseline in Number of Times Patient Was Wet at Catheterisation
Change from baseline in number of times patient was wet at time of catheterisation as recorded in catheterisation diary.
Time frame: Baseline and Week 14
Number of Participants With Clinically Relevant Abnormalities for Physical Examination, Vital Signs/Orthostatic Testing, Electorocardiogram (ECG), Laboratory Values, Urinalysis, Treatment Emergent AE's and Cognitive Testing.
Number of participants with Clinically Relevant Abnormalities for Physical Examination, Vital Signs/Orthostatic testing (blood pressure, pulse and respiratory rate), Electrocardiogram (ECG), Laboratory Values inclusive of hormonal assays, vision testing, Cognitive Testing, Occurrence of treatment emergent adverse events, Premature discontinuation of study drug due to AE and Urinalysis. Relevant findings or worsening of baseline conditions were reported as adverse events.
Time frame: From first drug administration until 28 days after last study drug administration, upto 160 days
Post Void Residual Volume at Week 14
Median change from baseline to Week 14 in post void residual (mL) by study treatment.
Time frame: Baseline and Week 14.
The trial included children from 2-16 years of age, with elevated detrusor leak point pressure associated with a known neurologic defect (e.g., spina bifida). The three age strata were 2-\<5 years, 5-\<10 years and 10-16 years of age. In this study, 231 subjects were enrolled, 162 subjects were randomised and 161 subjects were treated.
| Milestone | Placebo | Tamsulosin - Low Dose Level | Tamsulosin - Medium Dose Level | Tamsulosin - High Dose Level |
|---|---|---|---|---|
| Started | 41 | 40 | 39 | 41 |
| Not treated | 0 | 0 | 1 | 0 |
| Completed | 36 | 36 | 36 | 40 |
| Not completed | 5 | 4 | 3 | 1 |
| Withdrew: Adverse event | 1 | 2 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 2 | 0 |
| Withdrew: Lost to follow-up | 2 | 2 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 1 |
| Withdrew: Other than stated | 1 | 0 | 0 | 0 |
The primary endpoint was response to treatment defined as patients who decreased their detrusor leak point pressure (LPP) based upon two evaluations on the same day to less than 40 cm H2O at Week 14 (end of treatment). Detrusor leak point pressure (LPP) recorded in cm H2O was obtained using a standard urodynamic technique, a cystometrogram. On treatment (OT): Consist of all on treatment data. Observations measured ≤3 days of stopping treatment was considered as on treatment. Missing data in these analyses was not replaced or imputed.
| Percentage of participants | Placebo | Tamsulosin - Low Dose Level | Tamsulosin - Medium Dose Level | Tamsulosin - High Dose Level |
|---|---|---|---|---|
| Response to Treatment Defined as Patients Who Decrease Their Detrusor Leak Point Pressure (LPP) to <40 cm H2O Based Upon Two Evaluations on the Same Day. | 35.3 | 45.7 | 27.3 | 42.4 |
Change from baseline in detrusor leak point pressure (LPP) at Week 14 (end of treatment) between each dose group and the placebo group was compared for the FAS-LPP.
| cm H2O | Placebo | Tamsulosin - Low Dose Level | Tamsulosin - Medium Dose Level | Tamsulosin - High Dose Level |
|---|---|---|---|---|
| Change From Baseline in LPP at Week 14 (End of Treatment) | -11.4 ± 4.6 | -17.6 ± 4.5 | -4.6 ± 4.4 | -14.3 ± 4.3 |
Percent changes in detrusor leak point pressure (LPP) from baseline to the end of treatment at Week 14 between each dose group and the placebo group were compared for the FAS-LPP.
| Percentage change | Placebo | Tamsulosin - Low Dose Level | Tamsulosin - Medium Dose Level | Tamsulosin - High Dose Level |
|---|---|---|---|---|
| Percentage Change From Baseline in LPP at Week 14 (End of Treatment) | -19.9 ± 7.3 | -27.4 ± 7.1 | -1.9 ± 7 | -23.9 ± 6.9 |
Hydronephrosis response was defined as stabilisation or improvement of hydronephrosis measured by renal ultrasound at the end of treatment when compared to baseline, based on ultrasound grading. The lower or same grade at end of treatment compared to baseline is considered an improvement or stabilization
| Participants | Placebo | Tamsulosin - Low Dose Level | Tamsulosin - Medium Dose Level | Tamsulosin - High Dose Level |
|---|---|---|---|---|
| Left Kidney [N= 34; 34; 33; 40] | 32 | 31 | 31 | 37 |
| Right Kidney [N= 33; 34; 34; 40] | 31 | 33 | 30 | 38 |
Hydroureter response was defined as stabilisation or improvement based on change from baseline in the presence or absence of hydroureter at the end of treatment (Week 14). Response defined as stabilization or improvement of hydroureter measured by renal ultrasound compared to baseline by treatment group (Patients are classified according to the treatment they were taking at Week 14 or end of treatment) at Week 14.
| Participants | Placebo | Tamsulosin - Low Dose Level | Tamsulosin - Medium Dose Level | Tamsulosin - High Dose Level |
|---|---|---|---|---|
| Left Kidney (N= 34, 34, 33, 40) | 33 | 33 | 32 | 38 |
| Right Kidney (N= 33, 34, 34, 40) | 33 | 33 | 32 | 38 |
Change in baseline urine volumes obtained by catheterisation as recorded in catheterisation diary at Week 14.
| mL | Placebo | Tamsulosin - Low Dose Level | Tamsulosin - Medium Dose Level | Tamsulosin - High Dose Level |
|---|---|---|---|---|
| Change From Baseline in Urine Volume at Week 14 | -2.3 ± 14.0 | -32.2 ± 15.5 | 4.4 ± 16.3 | 3.3 ± 14.2 |
Change from baseline in number of times patient was wet at time of catheterisation as recorded in catheterisation diary.
| Times patient wet at catheterization | Placebo | Tamsulosin - Low Dose Level | Tamsulosin - Medium Dose Level | Tamsulosin - High Dose Level |
|---|---|---|---|---|
| Change From Baseline in Number of Times Patient Was Wet at Catheterisation | 0.3 ± 0.8 | -1.7 ± 0.9 | 0.0 ± 0.9 | -0.4 ± 0.8 |
Number of participants with Clinically Relevant Abnormalities for Physical Examination, Vital Signs/Orthostatic testing (blood pressure, pulse and respiratory rate), Electrocardiogram (ECG), Laboratory Values inclusive of hormonal assays, vision testing, Cognitive Testing, Occurrence of treatment emergent adverse events, Premature discontinuation of study drug due to AE and Urinalysis. Relevant findings or worsening of baseline conditions were reported as adverse events.
| Participants | Placebo | Tamsulosin - Low Dose Level | Tamsulosin - Medium Dose Level | Tamsulosin - High Dose Level |
|---|---|---|---|---|
| Occurrence of treatment emergent adverse events | 18 | 39 | 24 | 15 |
| Premature discontinuation of study drug due to AE | 1 | 2 | 0 | 0 |
| Sinus tachycardia | 0 | 0 | 0 | 1 |
Median change from baseline to Week 14 in post void residual (mL) by study treatment.
| mL | Placebo | Tamsulosin - Low Dose Level | Tamsulosin - Medium Dose Level | Tamsulosin - High Dose Level |
|---|---|---|---|---|
| Post Void Residual Volume at Week 14 | 3 ± 80.28 | -19 ± 66.4 | -1.5 ± 92.33 | 0.00 ± 58.67 |
Collected over From first drug administration until 28 days after last study drug administration, upto 160 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 1/41 (2.4%) | 13/41 (31.7%) |
| Tamsulosin - Low Dose Level | — | 1/120 (0.8%) | 19/120 (15.8%) |
| Tamsulosin - Medium Dose Level | — | 0/80 (0%) | 14/80 (17.5%) |
| Tamsulosin - High Dose Level | — | 0/40 (0%) | 8/40 (20%) |
| Event | Placebo | Tamsulosin - Low Dose Level | Tamsulosin - Medium Dose Level | Tamsulosin - High Dose Level |
|---|---|---|---|---|
| Shunt malfunctionInjury, poisoning and procedural complications | 1/41 | 0/120 | 0/80 | 0/40 |
| HaematomaVascular disorders | 1/41 | 0/120 | 0/80 | 0/40 |
| DeathGeneral disorders | 0/41 | 1/120 | 0/80 | 0/40 |
| Event | Placebo | Tamsulosin - Low Dose Level | Tamsulosin - Medium Dose Level | Tamsulosin - High Dose Level |
|---|---|---|---|---|
| Abdominal painGastrointestinal disorders | 6/41 | 1/120 | 1/80 | 0/40 |
| HeadacheNervous system disorders | 6/41 | 1/120 | 3/80 | 1/40 |
| Urinary tract infectionInfections and infestations | 4/41 | 8/120 | 2/80 | 5/40 |
| VomitingGastrointestinal disorders | 5/41 | 2/120 | 4/80 | 3/40 |
| NasopharyngitisInfections and infestations | 1/41 | 5/120 | 4/80 | 4/40 |
| ConstipationGastrointestinal disorders | 3/41 | 0/120 | 0/80 | 0/40 |
| InfluenzaInfections and infestations | 3/41 | 3/120 | 1/80 | 2/40 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/41 | 1/120 | 5/80 | 0/40 |
Treated Set (TS): Includes all patients who were documented to have taken at least one dose of randomised treatment.
| Age, Continuous(Years) | Placebo | Tamsulosin - Low Dose Level | Tamsulosin - Medium Dose Level | Tamsulosin - High Dose Level | Total |
|---|---|---|---|---|---|
| Mean | 8.4 ± 3.7 | 8.1 ± 4.2 | 8.1 ± 3.8 | 8.2 ± 4.3 | 8.2 ± 4.0 |
| Age, Customized(participants) | Placebo | Tamsulosin - Low Dose Level | Tamsulosin - Medium Dose Level | Tamsulosin - High Dose Level | Total |
|---|---|---|---|---|---|
| 2 to < 5 years | 7 | 8 | 7 | 8 | 30 |
| 5 to < 10 years | 18 | 17 | 17 | 18 | 70 |
| 10 to 16 years | 16 | 15 | 15 | 15 | 61 |
| Sex: Female, Male(Participants) | Placebo | Tamsulosin - Low Dose Level | Tamsulosin - Medium Dose Level | Tamsulosin - High Dose Level | Total |
|---|---|---|---|---|---|
| Female | 16 | 18 | 14 | 16 | 64 |
| Male | 25 | 22 | 25 | 25 | 97 |
The record gives a start of Jan 2008, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2012, 3 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tamsulosin